Journal for ImmunoTherapy of Cancer

ISSNs: 2051-1426

BMJ Publishing Group

Scopus rating (2025): CiteScore 16.6 SJR 4.114 SNIP 1.932

Indexed in DOAJ

Journal

Titles	Journal for ImmunoTherapy of Cancer Journal for immunotherapy of cancer
Additional searchable titles	Journal for immunotherapy of cancer, J Immunother
ISSNs	2051-1426
Publisher	BMJ Publishing Group
ZDB-ID	2719863-7

Keywords

ASJC Scopus subject areas

Library keywords

610 Medicine and health

Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma

Reschke, R., Budde, P., Zucht, H. D., Mangana, J., Dummer, R., Pfoehler, C. & Wistuba-Hamprecht, K. & 9 others, Weide, B., Hakim-Meibodi, L. E., Meier, F., Schulz, C., Richter, J., Bräutigam, M., Gutjahr, C., Schulz-Knappe, P. & Hassel, J. C., 27 Jan 2026, In: Journal for immunotherapy of cancer. 14, 1, e013814.

Research output: Contribution to journal › Research article › Contributed › peer-review

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma

Herold, N., Bochem, J., Leyens, J., Wingerter, S., Forchhammer, S., Spreuer, J. & Deseke, M. & 24 others, Yurttas, C., Nocerino, P., dos Reis, R. A., Amaral, T., Wagner, N. B., Thiel, K., Soffel, D., Bieber, K., Terheyden, P., Wesch, D., Oberg, H. H., Sebens, S., Claassen, M., Königsrainer, A., Garbe, C., Pawelec, G., Meier, F., Löffler, M. W., Weide, B., Prinz, I., Ravens, S., Kordasti, S., Eigentler, T. & Wistuba-Hamprecht, K., 20 Jan 2026, In: Journal for immunotherapy of cancer. 14, 1, 15 p., e011224.

Research output: Contribution to journal › Research article › Contributed › peer-review

Abscopal effects in patients with malignant melanoma treated with radiotherapy and immune checkpoint inhibition: analysis of a large observational multicenter study

Ferdinandus, S., Rühle, A., Lamrani, A., Frei, C., Kaufmann, J., Mäurer, M. & Wurschi, G. & 16 others, Jiang, P., Ehret, F., Baehr, A., Hardt, A., Bodensohn, R., Käsmann, L., Waltenberger, M., Scafa, D., Layer, J. P., Troost, E. G. C., Elkhamisy, S. A., Jazmati, D., Franklin, C., Neppl, S., Hagemeier, A. & Trommer, M., 2 Oct 2025, In: Journal for immunotherapy of cancer. 13, 10, e012717.

Research output: Contribution to journal › Research article › Contributed › peer-review

Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis

Oliva, K. N., Arnold, L., Heinzerling, L., Meier, F., Hartmann, S., Meier, K. & Huynh, J. & 6 others, Schlaak, M., Gesierich, A., Dirven, I., Trojan, J., Kleemann, J. & Schilling, B., 23 Sept 2025, In: Journal for immunotherapy of cancer. 13, 9, 6 p., e013038.

Research output: Contribution to journal › Research article › Contributed › peer-review

P-03.06 EGFL7, an angiogenic factor, induces immunosuppression in malignant glioma

Mahajan, S., Schumann, U. & Schmidt, M., 24 Mar 2025, In: Journal for ImmunoTherapy of Cancer. 13, Suppl 1

Research output: Contribution to journal › Meeting abstract › Contributed › peer-review

View all research output (18)

Research Portal of the TU Dresden

Journal for ImmunoTherapy of Cancer

Keywords

ASJC Scopus subject areas

Library keywords

Related content

Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma

Abscopal effects in patients with malignant melanoma treated with radiotherapy and immune checkpoint inhibition: analysis of a large observational multicenter study

Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis

P-03.06 EGFL7, an angiogenic factor, induces immunosuppression in malignant glioma